That turn­around on new FDA drug ap­provals? We’re right on sched­ule

We were due for a pret­ty good year on new drug ap­provals from the FDA, and so far the agency and the in­dus­try have been per­form­ing on sched­ule.

Last year at this time the FDA had record­ed just 7 new drug OKs on the way to a mis­er­able 22 new drug ap­provals for 2016. In a num­ber of cas­es the ane­mic rate of ap­provals was fed by tem­po­rary re­ver­sals based on man­u­fac­tur­ing sna­fus, a con­di­tion still acute­ly felt at As­traZeneca, which just had its sec­ond re­jec­tion on ZS-9.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER